Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine. 2005

Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
Institute of Experimental Biopharmaceutics, Joint Research Centre of the Czech Academy of Sciences and PRO.MED.CS Praha a.s., Hradec Králové, Czech Republic. svoboda@uebf.cas.cz

Galantamine (GAL) is a selective, competitive and reversible acetylcholinesterase (AChE) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of Alzheimer type. L-Carnitine (CAR) is a natural component of the mammalian tissue and is known to increase penetration of some chemical compounds/groups across biological membranes. The aim of this study was to evaluate the influence of pretreatment with CAR on AChE inhibition caused by GAL in selected brain parts in rat (basal ganglia, septum, frontal cortex, hippocampus) and in hypophysis, which does not lay beyond the blood-brain-barrier. During the first stage of the study, GAL was administered i.m. in different doses ranging from 2.5 to 10 mg/kg. The highest degree of AChE dose dependent inhibition was observed in hypophysis, while that in CNS was lower and became apparent in frontal cortex and hippocampus only after the administration of the dose of 10 mg/kg i.m. In the second stage, CAR was administered daily during 3 consecutive days at a dose of 250 mg/kg p.o. prior to the administration of GAL (10 mg/kg i.m.). Pretreatment with CAR enhanced trend of AChE inhibition in all selected brain parts comparing with single GAL administration, however, significant difference was not observed. Comparing these results with control group, statistical significance was found in frontal cortex, hippocampus and hypophysis.

UI MeSH Term Description Entries
D008297 Male Males
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002331 Carnitine A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism. Bicarnesine,L-Carnitine,Levocarnitine,Vitamin BT,L Carnitine
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005702 Galantamine A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. Galantamin,Galanthamine,Lycoremine,Reminyl,Galanthamine Hydrobromide,Nivalin,Nivaline,Razadyne
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
September 2021, Bioorganic & medicinal chemistry letters,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
March 2001, The journals of gerontology. Series A, Biological sciences and medical sciences,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
December 2006, Neuro endocrinology letters,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
June 2007, Biochemistry,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
January 1989, Pharmacological research,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
January 2016, Bioscience of microbiota, food and health,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
August 2005, Brain research,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
January 1989, Archives of gerontology and geriatrics,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
January 2010, Developmental neuroscience,
Zbynĕk Svoboda, and Jaroslav Kvĕtina, and Josef Herink, and Jirí Bajgar, and Lucie Bartosová, and Vladimír Palicka, and Pavel Zivný
October 1969, The Biochemical journal,
Copied contents to your clipboard!